Clinical value of miR-101-3p combined with PSPC1 detection in breast cancer disease and prognosis assessment

Yang Song; Zhang Jingya; Hou Yue; Zhang Wanli

doi:10.3969/j.issn.1671-6450.2025.08.014

Abstract：Objective To study the clinical value of miR-101-3p combined with PSPC1 detection in breast cancer condition and prognosis evaluation.Methods The research subjects were 107 breast cancer patients(BRC group)and 71 pa-tients with benign breast diseases(CON group)treated in the Department of Thyroid and Breast Surgery of Honghu People's Hospital from January 2019 to January 2022.Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression of miR-101-3p and PSPC1;Pearson correlation was used for correlation analysis;receiver operating characteris-tic(ROC)curve was used to analyze the sensitivity and specificity of miR-101-3p combined with PSPC1 in predicting poor prognosis of breast cancer;multivariate Logistic regression was used to analyze the risk factors for poor prognosis of breast cancer;Kaplan-Meier curve was used to analyze the relationship between miR-101-3p,PSPC1 expression and survival of breast cancer.Results The expression of miR-101-3p and PSPC1 in cancer tissues of BRC group was lower/higher than that in adjacent tissues of BRC group and CON group(F/P=158.778/＜0.001,467.306/＜0.001).The expression of miR-101-3p was low in patients with positive circulating tumor cells,pathological grade 3,primary lesion T stage T3-T4,lymph node N stage N2-N3,distant metastasis M stage M1 and stage Ⅲ-Ⅳ.In patients with negative circulating tumor cells,pathological grade 1-2,primary lesion T stage T1-T2,lymph node N stage N0-N1,distant metastasis M stage M0 and stage Ⅰ-Ⅱ(t/P=7.067/＜0.001,5.975/＜0.001,7.502/＜0.001,5.897/＜0.001,4.546/＜0.001,6.277/＜0.001),PSPC1 The expression was higher than that in patients with negative circulating tumor cells,pathological grade 1-2,primary lesion T stage T1-T2,lymph node N stage N0-N1,distant metastasis M stage M0 and stage Ⅰ-Ⅱ(t/P=5.178/＜0.001,5.687/＜0.001,6.114/＜0.001,4.505/＜0.001,3.655/＜0.001,5.156/＜0.001);BR The expression of miR-101-3p in group C was negatively correlated with circulating tumor cells,pathological grade,primary lesion T stage,lymph node N stage,distant metastasis M stage,and TNM stage(r/P=-0.711/0.029,-0.629/0.031,-0.616/0.007,-0.673/0.032,-0.644/0.018,-0.701/0.024),and PSPC1 expression was negatively correlated with the expression of miR-101-3p in group C(r/P=-0.711/0.029,-0.629/0.031,-0.616/0.007,-0.673/0.032,-0.644/0.018,-0.701/0.024).The expression of miR-101-3p,PSPC1 and their combination were positively correlated with circulating tumor cells,pathological grade,primary lesion T stage,lymph node N stage,distant metastasis M stage and TNM stage(r/P=0.688/0.014,0.645/0.009,0.638/0.022,0.627/0.038,0.652/0.041 and 0.676/0.009).The AUCs for poor prognosis in patients with adenocarcinoma were 0.629,0.607,and 0.872,respectively.The combined prediction of miR-101-3p and PSPC1 was su-perior to that of each alone(Z/P=7.174/0.001,6.048/0.005).Positive circulating tumor cells,pathological grade 3,primary le-sion T stage T3-T4,lymph node N stage N2-N3,distant metastasis M stage M1,TNM stage Ⅲ-Ⅳ,miR-101-3p ≤ 0.73,PSPC1 ≥0.89 were independent risk factors for poor prognosis of breast cancer[OR(95％CI)=1.525(1.035-2.015),2.457(1.131-3.783),1.726(1.098-2.354),2.077(1.124-3.030),2.487(1.133-3.841),the median survival time of patients with miR-101-3p ≤ 0.73 and PSPC1 ≥ 0.89 breast cancer was significantly lower than that of patients with miR-101-3p＞0.73 or PSPC1＜0.89(Log rank x2=11.952,P＜0.001).Conclusion The expression of miR-101-3p and PSPC1 in breast cancer is di-rectly related to the disease,prognosis and survival,and has a certain clinical value in the evaluation of breast cancer disease and prognosis.The combination of the two can synergistically improve the clinical value in breast cancer.